Certara, Inc. · NASDAQ:CERT

Certara — Technical Presentation (September 2012)

33 slides from Certara's technical presentation, Sep 12, 2012

  1. Slide 1: Model-based drug development in Multiple Sclerosis

    Model-based drug development in Multiple Sclerosis: Integrating disease, drug and market data for improved decision making Francois Mercier – Sep 12, 2012 © Certara, L.P. 2012 All Rights Reserved

  2. Slide 2: Today's Presenter

    Today’s Presenter Francois Mercier, Ph.D. • Senior Scientist, Pharsight Consulting Services • Previously with Fournier Pharma and Novartis • Involved in the clinical development of various compounds for the treatment of Multiple Sclerosis • Areas of expertise include exposure-response analysis, dose

  3. Slide 3: Introduction

    INTRODUCTION Slide 3 © Certara, L.P. 2012 All Rights Reserved

  4. Slide 4: Clinical Development in Multiple Sclerosis

    Clinical Development in Multiple Sclerosis Dysimmune Chronic lymphocytes Inflammatory disease lesions progression CNS Mainly young adults Affecting >2.5 mio. (2/3 women) people ww societal burden large indication • Treatments? “ABC-R”, fingolimod, natalizumab, … many more in development (BG-12, laqu

  5. Slide 5: Clinical Development in Multiple Sclerosis: Our Collective Challenges

    Clinical Development in Multiple Sclerosis Our Collective Challenges “My primary challenge in developing a new treatment for a neurodegenerative disease such as Multiple Sclerosis is…” Linking drug exposure and safety/tolerability 37.1% Understanding relationships btw biomarkers and clinical endpoin

  6. Slide 6: Model-based drug development

    Model-based drug development Disease Market Which Which patients? competitive edge? MBDD: “Development and application of pharmaco- statistical models of efficacy and safety data to improve drug development knowledge management and decision-making” Drug Which dose? Slide 6 © Certara, L.P. 2012 All R

  7. Slide 7: MBDD in MS

    MBDD in MS Challenges and opportunities Literature (summary) data I. Disease III. Market Which Competition Which patients? Model-based competitive Disease meta-analysis edge? progression Placebo, Safety historical profiling data PKPD Quantify efficacy and AE + rate trade-off Utility function Efficac

  8. Slide 8: I. Which Patients?

    I. WHICH PATIENTS? Slide 8 © Certara, L.P. 2012 All Rights Reserved

  9. Slide 9: Disease progression

    Disease progression “Disease progression” can be defined as: changes in disease status as a function of time. The goal of drug treatments in degenerative disorders is not only to relieve clinical symptoms, but also to slow disease progression. Clinical pharmacology = Disease progression + Drug Actio

  10. Slide 10: Disability progression

    Disability progression … does not stop after the first event In MS clinical development, the disability endpoint is usually expressed in terms of time to first confirmed disability progression (TFCP), defined as a 1 point increase on EDSS confirmed or augmented 3 months later (note: variants exist).

  11. Slide 11: Markov transition model

    Markov transition model A simple, intuitive alternative to model disability progression The goal of transition model is to estimate the transition matrix which defines the probability of switching from one EDSS level to another To: ≤2.5 3 or 3.5 4 or 4.5 ≥5 N From: ≤2.5 94.5% 4.3% 0.9% 0.3% 1684 3 o

  12. Slide 12: Characterize trends and identify influential covariates

    Characterize trends and identify influential covariates Favors disability progression Cumulative probability of confirmed disability progression in Placebo, low severity group Point-wise 95%CI Ref.: Base.EDSS [0, 2.5], Low Vol. T2, MSH≤5 years • Markov transition models for serial EDSS data have bee

  13. Slide 13: MBDD in MS

    MBDD in MS Challenges and opportunities Literature (summary) data I. Disease III. Market Which Competition Which patients? Model-based competitive Disease meta-analysis edge? progression Placebo, Safety historical profiling data PKPD Quantify efficacy and AE rate trade-off Utility function Efficacy

  14. Slide 14: II. Which Dose?

    II. WHICH DOSE? Slide 14 © Certara, L.P. 2012 All Rights Reserved

  15. Slide 15: PKPD modeling

    PKPD modeling To substantiate the choice of dose • S1P-receptor modulators (fingolimod, ponesimod, siponimod, ONO-4641, CS-0777) • Despite their recognized efficacy, appreciating the tolerability and safety risks associated with S1P-receptor modulators is primordial PK PD S1P1 Lymphocyte egress from

  16. Slide 16: PKPD model for efficacy

    PKPD model for efficacy • Lesion counts usually follow a NB or ZINB distribution1. Significant progress has been made in the PKPD modeling methodology for count data within the last 3-5 years2-3. • Another challenge is to gather the adequate data while keeping the clinical trial budget tight. This i

  17. Slide 17: PKPD model for safety: optimal lymphopenia

    PKPD model for safety Optimal degree and duration of lymphopenia Typical Imax values (%) IIV Fingolimod 87 1,2 Ponesimod - (~85%) 95%PI Siponimod 83 3 ONO-4641 83 4 CS-0777 85 5 Using a PKPD model, it is possible to S1Pr-modulator compounds share estimate the proportion of patients similar level of

  18. Slide 18: PKPD model for safety: dose titration

    PKPD model for safety Dose titration to address bradycardia PK PD AE “Following Gilenya: How follow-on S1P agonists could mitigate CV effects in MS? Dose Devil is in the dosing” E. McCallister (BioCentury, May 28 2012) HR CV event PK • PKPD models have been used to characterize the relationship betw

  19. Slide 19: Balancing efficacy and safety

    Balancing efficacy and safety weight of attribute i The CUI® is a multi-attribute utility1 that is normally calculated as: = drug attributes utility function utility = ½ (1 + ln(efficacy)) + ½ (1 + ln(safety)) for attribute i Various options to summarize compound-level efficacy and safety: • Effect

  20. Slide 20: MBDD in MS

    MBDD in MS Challenges and opportunities Literature (summary) data I. Disease III. Market Which Competition Which patients? Model-based competitive Disease meta-analysis edge? progression Placebo, Safety historical profiling data PKPD Quantify efficacy and AE rate trade-off Utility function Efficacy

  21. Slide 21: III. Which Competitive Edge?

    III. WHICH COMPETITIVE EDGE? Slide 21 © Certara, L.P. 2012 All Rights Reserved

  22. Slide 22: Model-based meta-analysis

    Model-based meta-analysis Leveraging literature data • Benchmark efficacy and safety — Evaluate new treatment options against other existing or emerging treatment options for go-no go decisions, dose selection, and trial strategy — Lack of active comparator trials in drug development; Meta-analyses

  23. Slide 23: Group-level lesion count data

    Group-level lesion count data Heterogeneous clinical practice mAb GA Teri small mol. Laq Fing Gd-enhanced lesions CUAL Avo Pbo Rit T2 lesions Reb Nat Ref.: Cohen 2007, Comi 2001, Comi 2008, Hauser 2008, Ocr Kappos 2006, Kappos 2011, Li 1999, Miller 2003, Dac O’Connor 2006, Panitch 2002, Polman 2005,

  24. Slide 24: Longitudinal lesion count and AE meta-analysis

    Longitudinal lesion count and AE meta-analysis • MBMA provide context for the development of new compounds • Support the definition of attributes of TPP BG12, Alemtuz-? Rit GA Fing Avo Ter Pla Slide 24 © Certara, L.P. 2012 All Rights Reserved

  25. Slide 25: MBDD in MS

    MBDD in MS Challenges and opportunities Literature (summary) data I. Disease III. Market Which Competition Which patients? Model-based competitive Disease meta-analysis edge? progression Placebo, Safety historical profiling data PKPD Quantify efficacy and AE rate trade-off Utility function Efficacy

  26. Slide 26: Conclusions

    CONCLUSIONS Slide 26 © Certara, L.P. 2012 All Rights Reserved

  27. Slide 27: Conclusions

    Conclusions 1) Large spectrum of expertise and data can be brought into the federative framework of M&S (a.k.a. Pharmacometrics) • Models can help separate “noise” from signal. • Models allow us to integrate data from different studies in a logical manner based on our understanding of the drug and d

  28. Slide 28: Upcoming Conferences

    Upcoming Conferences Opportunities to Meet and Discuss European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Oct 10-13, 2012 (Lyon, France) Poster: Model-based meta-analysis of lesion count time dynamics in MS http://www.congrex.ch/ectrims2012.html Joint BfArM/DIA Statistics

  29. Slide 29: Acknowledgments

    Acknowledgments • Colleagues at Pharsight Consulting Services, part of Certara™ • Colleagues at Novartis • In particular: G. Francis, P. Chin, E. Wallstroem, E. Pigeolet, O. Luttringer, D. Ohlssen, M. Mandel, L. Zhang-Auberson, F. Dahlke, S. Aksenov, R. Ramakrishna, K. Wu, C. Penland, R. Nixon, S. G

  30. Slide 30: Contacts & Follow-Up: Thank you!

    Contacts & Follow-Up: Thank you! For more information regarding today’s presentation, please contact: Francois Mercier, Ph.D. Senior Scientist Pharsight Consulting Services francois.mercier@certara.com For more information on Pharsight Consulting Services, please go to www.pharsight.com/services/ser

  31. Slide 31: References

    REFERENCES Slide 31 © Certara, L.P. 2012 All Rights Reserved

  32. Slide 32: References (1/2)

    References (1/2) Albert P.S. A Markov model for sequences of ordinal data from a relapsing-remitting disease. Biometrics, 1994; 50: 51–60. Chan P.L.S., Holford N.H.G. Drug treatment effects on disease progression. Annu. Rev. Pharmacol. Toxicol. 2001; 41: 625-59. Diggle P., Heagerty P., et al. Analys

  33. Slide 33: References (2/2)

    References (2/2) Mercier F., Mandel M., et al. Effect of fingolimod (FTY720) on disability progression: Application of a transition model to EDSS data collected in the FREEDOMS and TRANSFORMS trials. Poster P239 ECTRIMS, 2011, Amsterdam. Mercier F., Ohlssen D., et al. Characterization of dose-respon

Certara — Technical Presentation (September 2012) on 6ix